• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Alnylam Pharmaceuticals (ALNY) Could Be 53% Undervalued As Earnings And Trial Data Impress

    Simply Wall St·10/30/2026 03:38:46
    Listen to the news

    Why Alnylam Pharmaceuticals Stock Is Back in Focus

    Alnylam Pharmaceuticals (ALNY) just combined a big earnings surprise with fresh clinical data, giving investors new information on both current profitability and the longer term potential of its RNAi pipeline.

    Despite the strong quarter and fresh data, Alnylam Pharmaceuticals shares have come under pressure, with the 1-day share price return down 25.13% and the 30-day share price return down 31.51%, while the 3-year total shareholder return is still in positive territory, suggesting that long-term holders have experienced a very different journey compared with recent buyers.

    Seize this pullback in Alnylam Pharmaceuticals to reassess your biotech exposure alongside 36 healthcare AI stocks that could be reshaping how medicine and data intersect.

    Alnylam Pharmaceuticals is now down sharply from its recent levels, even after that earnings shock and pipeline update. Does it make more sense to step in after this drop or wait for valuation to reset further?

    Most Popular Narrative: 53% Undervalued

    At a last close of $174, the most followed narrative puts Alnylam Pharmaceuticals’ fair value at $371.35. This frames the current selloff as a large gap between price and what that narrative thinks the business is worth using a 7.64% discount rate.

    The broad RNAi portfolio at Alnylam Pharmaceuticals, with more than 25 programs across rare, specialty and prevalent conditions and multiple pivotal studies underway, creates repeated opportunities for new approvals that could add incremental revenue streams and help spread fixed R&D and SG&A over a larger sales base, which may support earnings.

    See why 29 investors see Alnylam Pharmaceuticals as 53% undervalued.

    Result: Fair Value of $371.35 (UNDERVALUED)

    Still, this Alnylam Pharmaceuticals story can change quickly if AMVUTTRA pricing pressure deepens or if high R&D spending outpaces future product uptake.

    Find out about the key risks to this Alnylam Pharmaceuticals narrative.

    Next Steps

    Feeling uncertain about whether this Alnylam Pharmaceuticals pullback reflects risk or opportunity, and recognizing that both possibilities exist, investors can move quickly to assess the 3 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond Alnylam Pharmaceuticals?

    If Alnylam Pharmaceuticals has your attention today, use that momentum to review fresh stock ideas that match clear goals, solid fundamentals, and your risk comfort.